Tuesday, April 23, 2013

Anolinx™ Utilizes Real World Data To Recruit Clinical Trials Patients Faster And With Greater Precision

Orlando, FL – Anolinx™, a clinical research and clinical trials recruitment company headquartered in Salt Lake City, Utah, announced today the launch of a new patient recruitment initiative.

Anolinx™ made the announcement in conjunction with the annual Partnerships in Clinical Trials conference in Orlando, FL.

According to Anolinx™ CEO, Aaron Kamauu MD MS MPH, the company is now poised to utilize real world “big data” for the purpose of recruiting patients for clinical trials. Dr. Kamauu, said at the press conference, “Our mission is quite simple: Use advanced analytics on current, deep and rich, real world data to identify and recruit clinical trials patients much faster and with greater precision. “

“Over the last two years we have proven the success of this model and are now prepared to launch our capabilities on a large scale. We have the analytics and the data to do this work,” he added.

Anolinx™ also announced two well-known thought leaders in healthcare as Chairman of the Board of Directors and Chairman of the Board of Advisors. Senator Robert F. Bennett will serve as Chairman of the Board of Directors and Raymond L.Woosley, MD PhD will serve as Chairman of the newly created Board of Scientific Advisors.

Senator Bennett, a former three-term Senator from Utah, is widely known for his healthcare expertise. While in the Senate he served as Chairman of the Appropriations Subcommittee on Agriculture, (the Senate committee with FDA budget oversight). He was also the co-author of the Bennett-Wyden healthcare bill, a health care proposal respected across the political spectrum as a common sense approach to healthcare reform. Senator Bennett also brings deep business experience to Anolinx™, having served as CEO of a NYSE traded public company prior to his Senate service.

“I am delighted to be joining Anolinx™,” said Senator Bennett. “I spent much of my Senate career on the committee that oversees the FDA budget. The cost and time to market of new medicines always have been major concerns, to drug manufacturers and consumers alike.What we are doing at Anolinx is the first real breakthrough I have seen in efforts to deal with these issues.”

Dr. Woosley is among the giants of medicine and clinical pharmacology in America. He was the Chair-man of the Department of Pharmacology and Associate Dean for Clinical Research at Georgetown

No comments: